Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured Confounding
Pharmaceutical Statistics · 2025
DOI: 10.1002/pst.2457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Douglas Faries und 9 weiteren Autor:innen. Beteiligte Einrichtung: Real-World Access and Analytics, Eli Lilly & Company, Indianapolis, USA. Hauptthemen laut MEDLINE: Observational Studies as Topic, Research Design. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
The assumption of “no unmeasured confounders” is a critical but unverifiable assumption required for causal inference yet quantitative sensitivity analyses to assess robustness of real‐world evidence remains under‐utilized. The lack of use is likely in part due to complexity of implementation and often specific and restrictive data requirements for application of each method. With the advent of methods that are broadly applicable in that they do not require identification of a specific unmeasured confounder—along with publicly available code for implementation—roadblocks toward broader use of sensitivity analyses are decreasing. To spur greater application, here we offer a good practice guidance to address the potential for unmeasured confounding at both the design and analysis stages, including framing questions and an analytic toolbox for researchers. The questions at the design stage guide the researcher through steps evaluating the potential robustness of the design while encouraging gathering of additional data to reduce uncertainty due to potential confounding. At the analysis stage, the questions guide quantifying the robustness of the observed result and providing researchers with a clearer indication of the strength of their conclusions. We demonstrate the application of this guidance using simulated data based on an observational fibromyalgia study, applying multiple methods from our analytic toolbox for illustration purposes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Real-World Access and Analytics, Eli Lilly & Company, Indianapolis, USA.
- Department of Statistics, North Carolina State University, Raleigh, North Carolina, USA.
- Medical Affairs Biostatistics, CSL Behring, King of Prussia, USA.
- Departments of Statistics & Data Science and Political Science, University of California at Los Angeles, Los Angeles, USA.
- Department of Statistical Science, Baylor University, Waco, USA.
- Department of Statistics, University of California Berkeley, Berkeley, USA.
ORCID-Profile: Douglas Faries, Shu Yang, Mingyang Shan, Nancy Dreyer
Förderung
- Eli Lilly and Company
Zitieren
APA
Faries, D., Gao, C., Zhang, X., Hazlett, C., Stamey, J., Yang, S., Ding, P., Shan, M., Sheffield, K., & Dreyer, N. (2025). Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured Confounding. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2457
Vancouver
Faries D, Gao C, Zhang X, Hazlett C, Stamey J, Yang S, et al. Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured Confounding. Pharmaceutical Statistics. 2025. doi:10.1002/pst.2457
BibTeX
@article{Faries2025,
author = {Faries, Douglas and Gao, Chenyin and Zhang, Xiang and Hazlett, Chad and Stamey, James and Yang, Shu and Ding, Peng and Shan, Mingyang and Sheffield, Kristin and Dreyer, Nancy},
title = {Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured Confounding},
journal = {Pharmaceutical Statistics},
year = {2025},
doi = {10.1002/pst.2457}
}
EUVIMED